| 2026-08-11 | Press release | Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability |
| 2026-08-04 | Document | HCP Action Required: Complete NEXPLANON REMS Certification by to Maintain Access to NEXPLANON® (etonoges |
| 2026-07-31 | Press release | Organon Announces Quarterly Dividend |
| 2026-07-31 | 8-K | Form 8-K, Item 7.01 |
| 2026-07-31 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-24 | Press release | New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improveme |
| 2026-07-23 | 8-K | Form 8-K, Item 5.07 |
| 2026-07-17 | 8-K | Form 8-K, Item 8.01 |
| 2026-07-16 | Press release | Press release · Q2 2026 · Jul 2026 |
| 2026-07-07 | Press release | Press release · Jul 2026 |
| 2026-06-22 | Press release | Press release · Jun 2026 |
| 2026-06-11 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-10 | Press release | June 10, 2026Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab |
| 2026-05-15 | Press release | May 15, 2026Organon to Present New Research on Access and Value at ISPOR 2026 |
| 2026-05-04 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-30 | Press release | Organon Reports Results for the First Quarter Ended March 31, 2026 |
| 2026-04-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-29 | Press release | European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA |
| 2026-04-29 | Press release | April 29, 2026Organon Cancels First Quarter Earnings Call · 2026 |
| 2026-04-27 | 8-K | Form 8-K, Item 1.01 |
| 2026-04-26 | Press release | April 26, 2026Organon’s Sale to Sun Pharma |
| 2026-04-24 | Proxy | Definitive proxy statement |
| 2026-04-16 | Press release | Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026 |
| 2026-04-15 | Press release | Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidel |
| 2026-03-27 | Press release | Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin |
| 2026-02-27 | Press release | New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient |
| 2026-02-24 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-23 | Press release | Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device |
| 2026-02-20 | 8-K | Form 8-K, Item 8.01 |
| 2026-02-12 | Press release | Organon Q4 2025 Financial Results |
| 2026-02-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-11 | Deck | Organon Q4 2025 Earnings Presentation |
| 2026-01-29 | Press release | Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026 |
| 2026-01-28 | Press release | Organon Completes Divestiture of JADA® System to Laborie |
| 2026-01-16 | Press release | Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Us |
| 2026-01-08 | Press release | Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo<sup>®</sup> in France, Denmark, Iceland |
| 2025-11-25 | Press release | Organon To Present at the Piper Sandler 37th Annual Healthcare Conference |
| 2025-11-17 | Press release | Henlius and Organon Announce US FDA Approval of POHERDY<sup>®</sup> (pertuzumab-dpzb), the First PERJETA (pertuzumab) Bi |
| 2025-11-10 | Press release | Organon Reports Results for the Third Quarter Ended September 30, 2025 |
| 2025-11-10 | 8-K | Form 8-K, Item 2.02 results |